Based on the Alector Inc stock forecast from 6 analysts, the average analyst target price for Alector Inc is USD 4.60 over the next 12 months. Alector Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Alector Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Alector Inc’s stock price was USD 1.02. Alector Inc’s stock price has changed by -20.93% over the past week, -34.19% over the past month and -82.53% over the last year.
No recent analyst target price found for Alector Inc
No recent average analyst rating found for Alector Inc
Company Overview Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Read Less
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical tr...Read More
Frequently Asked Questions About Alector Inc (ALEC) Stock
Based on ratings from 6 analysts Alector Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 3 sell and 3 hold ratings.
Unfortunately we do not have enough data on ALEC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ALEC is USD 4.60 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 1.
ALEC stock's Price/Earning ratio is 15.22.
Our analysis grades ALEC stock's Price / Earning ratio at F. This means that ALEC stock's Price/Earning ratio is above 64% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ALEC may be a overvalued for its sector.
The last closing price of ALEC's stock was USD 1.02.
The most recent market capitalization for ALEC is USD 0.14B.
Based on targets from 6 analysts, the average taret price for ALEC is projected at USD 4.60 over the next 12 months.
This means that ALEC's stock price may go up by +350.98% over the next 12 months.
We can't find any ETFs which contains Alector Inc's stock.
As per our most recent records Alector Inc has 238 Employees.
Alector Inc's registered address is 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Alector Inc's website at https://www.alector.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Alector Inc (ALEC) Stock
Based on ratings from 6 analysts Alector Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 3 sell and 3 hold ratings.
Unfortunately we do not have enough data on ALEC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ALEC is USD 4.60 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 1.
ALEC stock's Price/Earning ratio is 15.22.
Our analysis grades ALEC stock's Price / Earning ratio at F. This means that ALEC stock's Price/Earning ratio is above 64% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ALEC may be a overvalued for its sector.
The last closing price of ALEC's stock was USD 1.02.
The most recent market capitalization for ALEC is USD 0.14B.
Based on targets from 6 analysts, the average taret price for ALEC is projected at USD 4.60 over the next 12 months.
This means that ALEC's stock price may go up by +350.98% over the next 12 months.
We can't find any ETFs which contains Alector Inc's stock.
As per our most recent records Alector Inc has 238 Employees.
Alector Inc's registered address is 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Alector Inc's website at https://www.alector.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALEC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
